AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
elvitegravir 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| antivirals | 4300 | 697761-98-1 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
Elvitegravir inhibits the strand transfer activity of HIV-1 integrase (integrase strand transfer inhibitor; INSTI), an HIV-1 encoded enzyme that is required for viral replication. Inhibition of integrase prevents the integration of HIV-1 DNA into host genomic DNA, blocking the formation of the HIV-1 provirus and propagation of the viral infection. Elvitegravir does not inhibit human topoisomerases I or II.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
None
ADMET properties:
None
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| azlogd74 | LogD at pH 7.4 | 3.222 | High | 1 | |
| caco2-efflux | Caco-2 efflux ratio (BA/AB) | 2.438 | High | 1 | |
| caco2-intrinsic-papp | Caco-2 intrinsic apparent permeability | 71.450 | 10^-6 cm/s | High | 1 |
| dh-clint | Dog hepatocyte intrinsic clearance | 14.125 | uL/min/10^6 cells | High | 1 |
| dppb | Dog plasma protein binding (% unbound) | 1.090 | % | High | 1 |
| fcs-ppb | Fetal calf serum protein binding (% unbound) | 2.750 | % | High | 1 |
| herg | hERG pIC50 | 4.891 | pIC50 | High | 1 |
| hh-clint | Human hepatocyte intrinsic clearance | 36.224 | uL/min/10^6 cells | High | 1 |
| hlm-clint | Human liver microsomal intrinsic clearance | 110.917 | uL/min/mg protein | High | 1 |
| hppb | Human plasma protein binding (% unbound) | 0.740 | % | High | 1 |
| kinase-safety-class | ACVR2B,AXL,CDK5,EIF2AK3,ERBB2,GRK2,MAPK7,PDK1,PDK2,PDK4,PIK3CB,PIK3CG,PRKDC,TGFBR1 | 14 | |||
| kinase-selectivity-class | ACVR2B,AXL,BRAF,CDK9,DYRK1B,EIF2AK3,EPHB4,GRK2,MAP2K6,MAPK7,PDK4,PIK3CB,PIK3CD,PIK3CG,PRKDC,STK33,TEK,TGFBR1,TTK | 19 | |||
| mdck-mdr1-bcrp-efflux | MDCK-MDR1-BCRP efflux ratio | 2.838 | High | 1 | |
| mdck-mdr1-efflux | MDCK-MDR1 efflux ratio | 4.887 | High | 1 | |
| mh-clint | Mouse hepatocyte intrinsic clearance | 34.594 | High | 1 | |
| mppb | Mouse plasma protein binding (% unbound) | 0.760 | High | 1 | |
| nih-mdck-mdr1-efflux | NIH MDCK-MDR1 efflux ratio | 37.584 | High | 1 | |
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 | |||
| pppb | Pig plasma protein binding (% unbound) | 2.050 | % | High | 1 |
| rat-kpuu-brain | Rat brain Kpuu | 0.033 | % | High | 1 |
| rh-clint | Rat hepatocyte intrinsic clearance | 64.565 | uL/min/10^6 cells | High | 1 |
| rh-fuinc | Rat hepatocyte fraction unbound in incubation | 16.510 | % | High | 1 |
| rppb | Rat plasma protein binding (% unbound) | 0.640 | % | High | 1 |
| solubility-dd | Solubility at pH 7.4 in DMSO | 50.350 | uM | High | 1 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Aug. 27, 2012 | FDA | GILEAD SCIENCES INC | |
| March 25, 2013 | PMDA | Japan Tobacco Inc. | |
| May 24, 2013 | EMA | Gilead Sciences Ireland UC |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Renal dysplasia | 84.43 | 74.19 | 10 | 182 | 374 | 90627881 |
| Single functional kidney | 76.09 | 74.19 | 9 | 183 | 332 | 90627923 |
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Renal dysplasia | 64.81 | 50.05 | 7 | 390 | 62 | 110588840 |
| Single functional kidney | 54.29 | 50.05 | 7 | 390 | 303 | 110588599 |
| Drug interaction | 51.60 | 50.05 | 28 | 369 | 500155 | 110088747 |
| Drug resistance | 50.07 | 50.05 | 15 | 382 | 56359 | 110532543 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | J05AJ02 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIVIRALS FOR SYSTEMIC USE DIRECT ACTING ANTIVIRALS Integrase inhibitors |
| ATC | J05AR09 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIVIRALS FOR SYSTEMIC USE DIRECT ACTING ANTIVIRALS Antivirals for treatment of HIV infections, combinations |
| ATC | J05AR18 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIVIRALS FOR SYSTEMIC USE DIRECT ACTING ANTIVIRALS Antivirals for treatment of HIV infections, combinations |
| FDA MoA | N0000000127 | HIV Integrase Inhibitors |
| MeSH PA | D000890 | Anti-Infective Agents |
| MeSH PA | D000998 | Antiviral Agents |
| MeSH PA | D004791 | Enzyme Inhibitors |
| MeSH PA | D019380 | Anti-HIV Agents |
| MeSH PA | D019429 | Integrase Inhibitors |
| MeSH PA | D044966 | Anti-Retroviral Agents |
| FDA EPC | N0000175887 | Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor |
| FDA MoA | N0000185507 | Cytochrome P450 2C9 Inducers |
| CHEBI has role | CHEBI:22587 | antiviral agent |
| CHEBI has role | CHEBI:50864 | insulin-sensitizing drug |
| CHEBI has role | CHEBI:64946 | anti-HIV agent |
| CHEBI has role | CHEBI:67268 | HIV-1 integrase inhibitor |
Related Drugs by ATC class:
J05AJ Integrase inhibitors 3 drugs
J05AR Antivirals for treatment of HIV infections, combinations 19 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Human immunodeficiency virus infection | indication | 86406008 | DOID:526 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 6.37 | acidic |
| pKa2 | 12.88 | acidic |
| pKa3 | 3.44 | Basic |
Orange Book patent data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
|---|---|---|---|---|---|---|---|---|---|---|
| 150MG | VITEKTA | GILEAD SCIENCES INC | N203093 | Sept. 24, 2014 | DISCN | TABLET | ORAL | 7176220 | Aug. 27, 2026 | TREATMENT OF HIV INFECTION |
| 85MG | VITEKTA | GILEAD SCIENCES INC | N203093 | Sept. 24, 2014 | DISCN | TABLET | ORAL | 7176220 | Aug. 27, 2026 | TREATMENT OF HIV INFECTION |
| 150MG;150MG;200MG;300MG | STRIBILD | GILEAD SCIENCES INC | N203100 | Aug. 27, 2012 | RX | TABLET | ORAL | 7176220 | Aug. 27, 2026 | TREATMENT OF HIV INFECTION |
| 150MG;150MG;200MG;EQ 10MG BASE | GENVOYA | GILEAD SCIENCES INC | N207561 | Nov. 5, 2015 | RX | TABLET | ORAL | 7176220 | Aug. 27, 2026 | TREATMENT OF HIV INFECTION |
| 150MG | VITEKTA | GILEAD SCIENCES INC | N203093 | Sept. 24, 2014 | DISCN | TABLET | ORAL | 7635704 | Oct. 26, 2026 | TREATMENT OF HIV INFECTION |
| 85MG | VITEKTA | GILEAD SCIENCES INC | N203093 | Sept. 24, 2014 | DISCN | TABLET | ORAL | 7635704 | Oct. 26, 2026 | TREATMENT OF HIV INFECTION |
| 150MG;150MG;200MG;300MG | STRIBILD | GILEAD SCIENCES INC | N203100 | Aug. 27, 2012 | RX | TABLET | ORAL | 7635704 | Oct. 26, 2026 | TREATMENT OF HIV INFECTION |
| 150MG;150MG;200MG;EQ 10MG BASE | GENVOYA | GILEAD SCIENCES INC | N207561 | Nov. 5, 2015 | RX | TABLET | ORAL | 7635704 | Oct. 26, 2026 | TREATMENT OF HIV INFECTION |
| 150MG;150MG;200MG;300MG | STRIBILD | GILEAD SCIENCES INC | N203100 | Aug. 27, 2012 | RX | TABLET | ORAL | 8148374 | Sept. 3, 2029 | TREATMENT OF HIV INFECTION USING A COMPOSITION CONTAINING A PHARMACOKINETIC ENHANCER THAT INHIBITS CYTOCHROME P450 MONOOXYGENASE |
| 150MG;150MG;200MG;300MG | STRIBILD | GILEAD SCIENCES INC | N203100 | Aug. 27, 2012 | RX | TABLET | ORAL | 9891239 | Sept. 3, 2029 | TREATMENT OF HIV INFECTION |
| 150MG;150MG;200MG;EQ 10MG BASE | GENVOYA | GILEAD SCIENCES INC | N207561 | Nov. 5, 2015 | RX | TABLET | ORAL | 8148374 | Sept. 3, 2029 | TREATMENT OF HIV INFECTION USING A COMPOSITION CONTAINING A PHARMACOKINETIC ENHANCER THAT INHIBITS CYTOCHROME P450 MONOOXYGENASE |
| 150MG;150MG;200MG;EQ 10MG BASE | GENVOYA | GILEAD SCIENCES INC | N207561 | Nov. 5, 2015 | RX | TABLET | ORAL | 9891239 | Sept. 3, 2029 | TREATMENT OF HIV INFECTION |
| 150MG;150MG;200MG;300MG | STRIBILD | GILEAD SCIENCES INC | N203100 | Aug. 27, 2012 | RX | TABLET | ORAL | 8633219 | April 30, 2030 | TREATMENT OF HIV INFECTION |
| 150MG;150MG;200MG;EQ 10MG BASE | GENVOYA | GILEAD SCIENCES INC | N207561 | Nov. 5, 2015 | RX | TABLET | ORAL | 8633219 | April 30, 2030 | TREATMENT OF HIV INFECTION |
| 150MG;150MG;200MG;EQ 10MG BASE | GENVOYA | GILEAD SCIENCES INC | N207561 | Nov. 5, 2015 | RX | TABLET | ORAL | 8754065 | Aug. 15, 2032 | TREATMENT OF HIV INFECTION |
| 150MG;150MG;200MG;EQ 10MG BASE | GENVOYA | GILEAD SCIENCES INC | N207561 | Nov. 5, 2015 | RX | TABLET | ORAL | 9296769 | Aug. 15, 2032 | TREATMENT OF HIV INFECTION |
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Integrase | Enzyme | INHIBITOR | IC50 | 8.14 | CHEMBL | CHEMBL | |||
| Integrase | Enzyme | IC50 | 8.75 | CHEMBL | |||||
| Gag-Pol polyprotein | Polyprotein | IC50 | 8 | WOMBAT-PK | |||||
| Reverse transcriptase/RNaseH | Enzyme | IC50 | 4.04 | CHEMBL | |||||
| Reverse transcriptase | Enzyme | IC50 | 4.04 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 4031665 | VUID |
| N0000185512 | NUI |
| D06677 | KEGG_DRUG |
| 4031665 | VANDF |
| CHEBI:72289 | CHEBI |
| ELV | PDB_CHEM_ID |
| CHEMBL204656 | ChEMBL_ID |
| C509700 | MESH_SUPPLEMENTAL_RECORD_UI |
| 11574 | IUPHAR_LIGAND_ID |
| DB09101 | DRUGBANK_ID |
| 4GDQ854U53 | UNII |
| 1306286 | RXNORM |
| 28749 | MMSL |
| d07898 | MMSL |
| 014621 | NDDF |
| 708828000 | SNOMEDCT_US |
| 714795001 | SNOMEDCT_US |
| C2606637 | UMLSCUI |
| 8871 | INN_ID |
| 5277135 | PUBCHEM_CID |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Stribild | HUMAN PRESCRIPTION DRUG LABEL | 4 | 53808-0887 | TABLET, FILM COATED | 150 mg | ORAL | NDA | 30 sections |
| Stribild | HUMAN PRESCRIPTION DRUG LABEL | 4 | 61958-1201 | TABLET, FILM COATED | 150 mg | ORAL | NDA | 31 sections |
| Genvoya | HUMAN PRESCRIPTION DRUG LABEL | 4 | 61958-1901 | TABLET | 150 mg | ORAL | NDA | 32 sections |
| Stribild | HUMAN PRESCRIPTION DRUG LABEL | 4 | 69189-1201 | TABLET, FILM COATED | 150 mg | ORAL | NDA | 30 sections |